Processa Pharmaceuticals PCSA

Processa Pharmaceuticals, Inc. is a publicly listed clinical stage biopharmaceutical company focused on developing Next Generation Cancer therapy small molecules. The firm creates modified versions of existing cancer drugs to improve efficacy and reduce toxicity by altering how the body metabolizes or distributes these agents. Its oncology pipeline includes NGC Cap, which is a small molecule currently in a Phase 2 trial for advanced or metastatic breast cancer, and NGC Iri, which remains in preclinical development. The company also advances non oncology candidates such as PCS12852, a 5HT4 irreversible agonist for gastroparesis, and PCS499, which is being evaluated for primary glomerular diseases. In June 2025, Processa entered into a binding term sheet with Intact Therapeutics granting Intact an exclusive option to license PCS12852, and it extended an existing agreement with Yuhan Corporation to extend clinical trial timelines for the same asset. Additionally, the company terminated its licensing agreement for NGC Gem (PCS3117) with Ocuphire Pharma in June 2025, with the termination becoming effective in October 2025. All development efforts are guided by the firm’s proprietary Regulatory Science Approach designed to improve the likelihood of regulatory approval.

Processa Pharmaceuticals, Inc. does not currently generate product revenue because none of its drug candidates have received regulatory approval for sale. The company anticipates future revenue from the commercialization of its oncology and non oncology therapies, as well as from licensing agreements, milestone payments, and royalties with partners such as Intact Therapeutics and Yuhan Corporation. In the near term, the firm relies on proceeds from public equity offerings, warrant exercises, and its cryptocurrency treasury strategy to fund research and development activities. During the nine months ended September 30, 2025, Processa raised net proceeds of $10.6 million from two public offerings and received $728,000 from the exercise of warrants sold in the June offering. As of November 3, 2025, the company held $850,000 in Digital Assets after transferring funds into a crypto wallet managed by Cube Operations LLC. These financing activities provide the working capital needed to continue clinical trials for NGC Cap and to support preclinical work on other pipeline assets.

Processa Pharmaceuticals, Inc. operates within the highly competitive clinical stage biopharmaceutical sector, where many companies pursue incremental improvements to established cancer treatments. Its competitive advantage lies in a risk mitigated strategy that targets well understood, cornerstone therapies with known toxicity and then applies its proprietary Regulatory Science Approach to enhance safety and efficacy. This approach aims to increase the likelihood of regulatory approval and to accelerate commercial adoption relative to novel molecular entities that face higher development uncertainty. While the filing does not name specific rivals, the company differentiates itself from larger pharmaceutical firms by focusing on repurposing active metabolites rather than inventing new chemical structures, which can reduce preclinical risk and development costs. Additionally, the firm’s emphasis on existing indications with large patient populations may facilitate faster uptake if clinical outcomes demonstrate superior tolerability and effectiveness compared with standard of care.

Processa Pharmaceuticals, Inc. serves patients, hospitals, and healthcare providers through its future therapeutic products once they receive regulatory approval and reach the market. The company also engages with corporate partners for licensing and development, including Intact Therapeutics, which holds an option to license PCS12852 for gastroparesis, and Yuhan Corporation, which maintains an existing agreement for the same asset. Additional interactions involve CorLyst, which provides reimbursement support for certain clinical activities, and former licensing counterpart Ocuphire Pharma (now Opus Genetics) for the NGC Gem program prior to its termination in October 2025. Processa collaborates with contract research organizations and clinical investigators to conduct its Phase 2 trial for NGC Cap and its preclinical studies for other pipeline assets. These relationships with investigators, sites, and vendors are essential for advancing the company’s drug candidates toward potential commercialization.